Zymeworks (ZYME) stock: insider trades, news & valuation
Heavy sellingShare price and insider trades
Zymeworks insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 5 sold $5.0M of ZYME stock on the open market.
Get emailed when insiders cluster-buy stocks like ZYME
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
ZYME insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $358K | 1 |
| Q3 2026 | — | 0 | — | 0 |
| Q2 2026 | — | 0 | — | 0 |
| Q1 2026 | — | 0 | $3.4M | 9 |
| Q4 2025 | — | 0 | $1.3M | 1 |
Valuation, profit and volume
Summary
Over the past 12 months, 0 Zymeworks Inc. insiders reported open-market purchases totaling $0, while 5 insiders reported sales totaling $5.0M. 0 of 11 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Oct 9 NewSEC | Adam SchayowitzEvp, Head Of R&D | Sell | 13,83223,205 held (−37%) | $25.85 | $358K | -0.2% | — |
| Jan 13SEC | Mark HollywoodCOO | Sell | 6,120132,913 held (−4%) | $22.67 | $139K | +13.8% | — |
| Jan 12SEC | Kenneth GalbraithCEO, Chair | Sell | 30,424226,842 held (−12%) | $22.67 | $690K | +13.8% | — |
| Jan 12SEC | Paul Andrew MooreChief Scientific Officer | Sell | 9,56048,497 held (−16%) | $22.67 | $217K | +13.8% | — |
| Jan 12SEC | Jeffrey T L SmithEvp & Chief Medical Officer | Sell | 9,31026,708 held (−26%) | $22.67 | $211K | +13.8% | — |
| Jan 5SEC | Kenneth GalbraithCEO, Chair | Sell | 31,686193,266 held (−14%) | $25.10 | $795K | +2.7% | — |
| Jan 5SEC | Kenneth GalbraithCEO, Chair | Sell | 22,657158,286 held (−13%) | $25.10 | $569K | +2.7% | — |
| Jan 5SEC | Paul Andrew MooreChief Scientific Officer | Sell | 10,82140,391 held (−21%) | $25.10 | $272K | +2.7% | — |
| Jan 5SEC | Jeffrey T L SmithEvp & Chief Medical Officer | Sell | 10,53818,352 held (−36%) | $25.10 | $265K | +2.7% | — |
| Jan 5SEC | Paul Andrew MooreChief Scientific Officer | Sell | 9,28931,212 held (−23%) | $25.10 | $233K | +2.7% | — |
| Dec 22SEC | Kenneth GalbraithCEO, Chair | Sell | 47,528133,275 held (−26%) | $27.02 | $1.3M | -4.6% | — |
Insiders at Zymeworks Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Kenneth GalbraithCEO, Chair | — | $3.3M | Jan 12, 2026 | — |
| Paul Andrew MooreChief Scientific Officer | — | $721K | Jan 12, 2026 | — |
| Jeffrey T L SmithEvp & Chief Medical Officer | — | $476K | Jan 12, 2026 | — |
| Adam SchayowitzEvp, Head Of R&D | — | $358K | Oct 9, 2026 | — |
| Mark HollywoodCOO | — | $139K | Jan 13, 2026 | — |
ZYME stock: common questions
Are Zymeworks Inc. insiders buying ZYME stock?
In the past 12 months, 0 insiders reported open-market purchases of ZYME worth $0.
Are Zymeworks Inc. insiders selling ZYME stock?
5 insiders reported sales worth $5.0M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is ZYME's 52-week range?
Over the past year ZYME has traded between $16.46 and $31.05. It last closed at $25.79 on Oct 9, 2026.